clinical trial · NCT07145229
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
Atom Therapeutics Co., Ltd·phase2·recruiting·n = 380
Acute Gouty ArthritisGout FlareGout FlaresAcute Gout FlareABP-745 Dose AABP-745 Dose BColchicinePlacebo
brief summary
A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in participants with acute gout. The primary efficacy measurement will be pain score after treatment.
started
Aug 26, 2025
primary completion
May 1, 2026
completion
Jun 1, 2026
last updated
Dec 8, 2025
official title
A Randomized, Double-blind, Multicenter, Colchicine and Placebo-controlled Study to Evaluate the Efficacy and Safety of ABP-745 in Subjects With an Acute Gout Flare
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol